FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3126319313> ?p ?o ?g. }

• W3126319313 endingPage "314" @default.
• W3126319313 startingPage "304" @default.
• W3126319313 abstract "Colorectal cancer screening programmes worldwide have been disrupted during the COVID-19 pandemic. We aimed to estimate the impact of hypothetical disruptions to organised faecal immunochemical test-based colorectal cancer screening programmes on short-term and long-term colorectal cancer incidence and mortality in three countries using microsimulation modelling.In this modelling study, we used four country-specific colorectal cancer microsimulation models-Policy1-Bowel (Australia), OncoSim (Canada), and ASCCA and MISCAN-Colon (the Netherlands)-to estimate the potential impact of COVID-19-related disruptions to screening on colorectal cancer incidence and mortality in Australia, Canada, and the Netherlands annually for the period 2020-24 and cumulatively for the period 2020-50. Modelled scenarios varied by duration of disruption (3, 6, and 12 months), decreases in screening participation after the period of disruption (0%, 25%, or 50% reduction), and catch-up screening strategies (within 6 months after the disruption period or all screening delayed by 6 months).Without catch-up screening, our analysis predicted that colorectal cancer deaths among individuals aged 50 years and older, a 3-month disruption would result in 414-902 additional new colorectal cancer diagnoses (relative increase 0·1-0·2%) and 324-440 additional deaths (relative increase 0·2-0·3%) in the Netherlands, 1672 additional diagnoses (relative increase 0·3%) and 979 additional deaths (relative increase 0·5%) in Australia, and 1671 additional diagnoses (relative increase 0·2%) and 799 additional deaths (relative increase 0·3%) in Canada between 2020 and 2050, compared with undisrupted screening. A 6-month disruption would result in 803-1803 additional diagnoses (relative increase 0·2-0·4%) and 678-881 additional deaths (relative increase 0·4-0·6%) in the Netherlands, 3552 additional diagnoses (relative increase 0·6%) and 1961 additional deaths (relative increase 1·0%) in Australia, and 2844 additional diagnoses (relative increase 0·3%) and 1319 additional deaths (relative increase 0·4%) in Canada between 2020 and 2050, compared with undisrupted screening. A 12-month disruption would result in 1619-3615 additional diagnoses (relative increase 0·4-0·9%) and 1360-1762 additional deaths (relative increase 0·8-1·2%) in the Netherlands, 7140 additional diagnoses (relative increase 1·2%) and 3968 additional deaths (relative increase 2·0%) in Australia, and 5212 additional diagnoses (relative increase 0·6%) and 2366 additional deaths (relative increase 0·8%) in Canada between 2020 and 2050, compared with undisrupted screening. Providing immediate catch-up screening could minimise the impact of the disruption, restricting the relative increase in colorectal cancer incidence and deaths between 2020 and 2050 to less than 0·1% in all countries. A post-disruption decrease in participation could increase colorectal cancer incidence by 0·2-0·9% and deaths by 0·6-1·6% between 2020 and 2050, compared with undisrupted screening.Although the projected effect of short-term disruption to colorectal cancer screening is modest, such disruption will have a marked impact on colorectal cancer incidence and deaths between 2020 and 2050 attributable to missed screening. Thus, it is crucial that, if disrupted, screening programmes ensure participation rates return to previously observed rates and provide catch-up screening wherever possible, since this could mitigate the impact on colorectal cancer deaths.Cancer Council New South Wales, Health Canada, and Dutch National Institute for Public Health and Environment." @default.
• W3126319313 created "2021-02-15" @default.
• W3126319313 creator A5000106236 @default.
• W3126319313 creator A5002356179 @default.
• W3126319313 creator A5007964616 @default.
• W3126319313 creator A5029845023 @default.
• W3126319313 creator A5036257389 @default.
• W3126319313 creator A5036395355 @default.
• W3126319313 creator A5039831424 @default.
• W3126319313 creator A5040466517 @default.
• W3126319313 creator A5058594959 @default.
• W3126319313 creator A5068086674 @default.
• W3126319313 creator A5073565334 @default.
• W3126319313 creator A5082385214 @default.
• W3126319313 creator A5083842584 @default.
• W3126319313 date "2021-04-01" @default.
• W3126319313 modified "2023-10-17" @default.
• W3126319313 title "Impact of the COVID-19 pandemic on faecal immunochemical test-based colorectal cancer screening programmes in Australia, Canada, and the Netherlands: a comparative modelling study" @default.
• W3126319313 cites W1860834513 @default.
• W3126319313 cites W2001324925 @default.
• W3126319313 cites W2071766180 @default.
• W3126319313 cites W2113110786 @default.
• W3126319313 cites W2337253348 @default.
• W3126319313 cites W2402516431 @default.
• W3126319313 cites W2676120491 @default.
• W3126319313 cites W2770600463 @default.
• W3126319313 cites W2778780785 @default.
• W3126319313 cites W2974736765 @default.
• W3126319313 cites W2978644288 @default.
• W3126319313 cites W3004924406 @default.
• W3126319313 cites W3023041338 @default.
• W3126319313 cites W3042226836 @default.
• W3126319313 cites W3081250284 @default.
• W3126319313 cites W3126648676 @default.
• W3126319313 doi "https://doi.org/10.1016/s2468-1253(21)00003-0" @default.
• W3126319313 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33548185" @default.
• W3126319313 hasPublicationYear "2021" @default.
• W3126319313 type Work @default.
• W3126319313 sameAs 3126319313 @default.
• W3126319313 citedByCount "87" @default.
• W3126319313 countsByYear W31263193132021 @default.
• W3126319313 countsByYear W31263193132022 @default.
• W3126319313 countsByYear W31263193132023 @default.
• W3126319313 crossrefType "journal-article" @default.
• W3126319313 hasAuthorship W3126319313A5000106236 @default.
• W3126319313 hasAuthorship W3126319313A5002356179 @default.
• W3126319313 hasAuthorship W3126319313A5007964616 @default.
• W3126319313 hasAuthorship W3126319313A5029845023 @default.
• W3126319313 hasAuthorship W3126319313A5036257389 @default.
• W3126319313 hasAuthorship W3126319313A5036395355 @default.
• W3126319313 hasAuthorship W3126319313A5039831424 @default.
• W3126319313 hasAuthorship W3126319313A5040466517 @default.
• W3126319313 hasAuthorship W3126319313A5058594959 @default.
• W3126319313 hasAuthorship W3126319313A5068086674 @default.
• W3126319313 hasAuthorship W3126319313A5073565334 @default.
• W3126319313 hasAuthorship W3126319313A5082385214 @default.
• W3126319313 hasAuthorship W3126319313A5083842584 @default.
• W3126319313 hasBestOaLocation W31263193131 @default.
• W3126319313 hasConcept C120665830 @default.
• W3126319313 hasConcept C121332964 @default.
• W3126319313 hasConcept C121608353 @default.
• W3126319313 hasConcept C126322002 @default.
• W3126319313 hasConcept C127413603 @default.
• W3126319313 hasConcept C144024400 @default.
• W3126319313 hasConcept C149923435 @default.
• W3126319313 hasConcept C22212356 @default.
• W3126319313 hasConcept C2779134260 @default.
• W3126319313 hasConcept C2780015235 @default.
• W3126319313 hasConcept C3008058167 @default.
• W3126319313 hasConcept C44249647 @default.
• W3126319313 hasConcept C524204448 @default.
• W3126319313 hasConcept C526805850 @default.
• W3126319313 hasConcept C61511704 @default.
• W3126319313 hasConcept C71924100 @default.
• W3126319313 hasConcept C82789193 @default.
• W3126319313 hasConcept C89623803 @default.
• W3126319313 hasConcept C99454951 @default.
• W3126319313 hasConceptScore W3126319313C120665830 @default.
• W3126319313 hasConceptScore W3126319313C121332964 @default.
• W3126319313 hasConceptScore W3126319313C121608353 @default.
• W3126319313 hasConceptScore W3126319313C126322002 @default.
• W3126319313 hasConceptScore W3126319313C127413603 @default.
• W3126319313 hasConceptScore W3126319313C144024400 @default.
• W3126319313 hasConceptScore W3126319313C149923435 @default.
• W3126319313 hasConceptScore W3126319313C22212356 @default.
• W3126319313 hasConceptScore W3126319313C2779134260 @default.
• W3126319313 hasConceptScore W3126319313C2780015235 @default.
• W3126319313 hasConceptScore W3126319313C3008058167 @default.
• W3126319313 hasConceptScore W3126319313C44249647 @default.
• W3126319313 hasConceptScore W3126319313C524204448 @default.
• W3126319313 hasConceptScore W3126319313C526805850 @default.
• W3126319313 hasConceptScore W3126319313C61511704 @default.
• W3126319313 hasConceptScore W3126319313C71924100 @default.
• W3126319313 hasConceptScore W3126319313C82789193 @default.
• W3126319313 hasConceptScore W3126319313C89623803 @default.
• W3126319313 hasConceptScore W3126319313C99454951 @default.
• W3126319313 hasFunder F4320334392 @default.
• W3126319313 hasFunder F4320334715 @default.

• next